Moving Beyond BRCA-Incorporating Molecular Assays into Ovarian Cancer Trials

Michelle McMullen; Katherine Karakasis; Amit M Oza

doi:10.1158/1078-0432.CCR-20-2429

Moving Beyond BRCA-Incorporating Molecular Assays into Ovarian Cancer Trials

Clin Cancer Res. 2020 Oct 15;26(20):5271-5273. doi: 10.1158/1078-0432.CCR-20-2429. Epub 2020 Aug 14.

Authors

Michelle McMullen¹, Katherine Karakasis¹, Amit M Oza^{2

3}

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network. Toronto, Ontario, Canada.
² Princess Margaret Cancer Centre, University Health Network. Toronto, Ontario, Canada. amit.oza@uhn.ca.
³ Department of Medicine, University of Toronto. Toronto, Ontario, Canada.

PMID: 32816948
DOI: 10.1158/1078-0432.CCR-20-2429

Abstract

PrOTYPE is a locked down assay validated to Institute of Medicine standards, using NanoString technology to classify high-grade serous ovarian cancer into four defined subgroups. Future directions will include prospective-retrospective analysis and prospective clinical validation to define the predictive role of this assay and its role in influencing treatment decisions.See related article by Talhouk et al., p. 5411.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Ovarian Epithelial
Female
Gene Expression
Humans
Ovarian Neoplasms* / diagnosis
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / genetics
Prospective Studies
Retrospective Studies